Form 4: Disc Medicine CFO Sells Shares Under Pre-Planned Program

Disc Medicine's Chief Financial Officer, Jean M. Franchi, reported sales of common stock, including a 'sell to cover' transaction and sales under a Rule 10b5-1 plan.

Summary

• Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (IRON), reported sales of the company's common stock.
• A total of 4,075 shares were sold on February 17, 2026, at a price of $62.86 per share, to cover tax withholding obligations related to the vesting of restricted stock units. This was a non-discretionary 'sell to cover' transaction.
• An additional 3,397 shares were sold on February 18, 2026, at a weighted average price of $65.0097 per share, as part of a Rule 10b5-1 trading plan.
• Another 3,684 shares were sold on February 18, 2026, at a weighted average price of $65.8889 per share, also under the same Rule 10b5-1 trading plan.
• The Rule 10b5-1 trading plan was adopted on September 25, 2025.
• Following these transactions, Jean M. Franchi beneficially owns 71,343 shares of Disc Medicine common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales are either for tax obligations or part of a pre-scheduled trading plan, rather than a discretionary sale indicating a change in management's outlook on the company's future.

Negatives

• The transactions resulted in a reduction of the Chief Financial Officer's direct beneficial ownership in Disc Medicine common stock by 11,156 shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under pre-arranged Rule 10b5-1 trading plans or for routine tax withholding purposes, are common occurrences. Such transactions typically carry less negative signaling compared to discretionary, unplanned sales, as they often reflect personal financial planning rather than a change in the insider's outlook on the company's prospects.

Stakeholder Impact

• Shareholders may observe a slight reduction in insider ownership, though the nature of the sales (tax cover, 10b5-1 plan) mitigates concerns about management's confidence.

Key Dates

Recommendation

The sales by the CFO are routine, either for tax obligations or under a pre-established 10b5-1 plan, and do not signal a change in the company's fundamentals or management's confidence. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment thesis.

Keywords

Disc Medicine, IRON, Form 4, Insider Trading, Stock Sale, CFO, 10b5-1 Plan, Sell to Cover, Equity Compensation